Cognitive Enhancement & Nootropic Drive
Identity map for Semax, Selank, Noopept, and related nootropic SKUs. BDNF language is mechanism, not a US cognition or stroke indication.
Full stacking map, tiers, and monitoring notes live on the protocol page — this hub only lists the compounds already named for this goal.
Compounds on this goal
Semax
cognitiveACTH(4-10) analog. BDNF/TrkB papers exist. That is mechanism, not a US cognition indication.
Open peptide leaf →Selank
cognitiveTuftsin analog with powerful anxiolytic effects; stabilizes endogenous enkephalins to keep the user calm but highly alert.
Open peptide leaf →Noopept
cognitiveDipeptide ester (omberacetam / GVS-111). Oral/nasal nootropic identity — not Semax, not a SubQ peptide. Russian outpatient doses in opened papers cluster around 20 mg/day as study context.
Open peptide leaf →Dihexa
cognitiveAngiotensin-IV / HGF-mimetic research amide. The "10 million times BDNF" line is an assay comparison, not a clinical multiplier.
Open peptide leaf →Evidence note on this goal
Protocol evidence level (from existing goal data): Emerging
- Semax and Selank are not FDA-approved; most clinical data comes from Russian studies with limited Western replication
- Dihexa is purely preclinical - no human clinical trials have been published
- Long-term safety of sustained BDNF upregulation in humans is not established
- Intranasal bioavailability varies significantly based on formulation and individual nasal anatomy